Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Next Previous
Trial Profile

A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KT 474 (Primary)
  • Indications Atopic dermatitis; Autoimmune disorders; Hidradenitis suppurativa; Multiple sclerosis; Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Kymera Therapeutics

Most Recent Events

  • 09 May 2025 According to a Kymera Therapeutics media release, results form this trial published in the Journal of Clinical and Translational Science.
  • 13 Nov 2023 Results published in a Kymera Therapeutics media release.
  • 13 Nov 2023 According to a Kymera Therapeutics media release, today announced results from the positive Phase 1 clinical trial of KT-474 (SAR444656), were published in Nature Medicine. The full manuscript, ''IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial,'' was published online on Nov 13, 2023, on the Nature Medicine website.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top